TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron Limited ( (AU:IMC) ) has provided an update.
Immuron Limited reported a 69.6% increase in revenue from ordinary activities, reaching $3,994,341 for the half-year ending December 31, 2024. Despite the revenue growth, the company experienced a 20% increase in losses, amounting to $2,488,819. The net tangible asset backing per share decreased from 7.62 cents to 4.46 cents. No dividends were declared for the current or previous financial period, and there were no changes in controlled entities. The financial statements were reviewed without any modifications by the independent auditor.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutic products for the treatment of gut-mediated diseases. The company primarily targets markets related to gastrointestinal health.
Average Trading Volume: 31,579
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €11.61M
See more insights into IMC stock on TipRanks’ Stock Analysis page.